Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of "Buy" by Brokerages

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $82.50.

Several research analysts recently issued reports on AKRO shares. Bank of America lifted their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. Citigroup cut their price target on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th.

Insider Transactions at Akero Therapeutics

In other Akero Therapeutics news, CFO William Richard White sold 1,634 shares of the firm's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total value of $89,608.56. Following the sale, the chief financial officer directly owned 57,521 shares of the company's stock, valued at approximately $3,154,451.64. This trade represents a 2.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Scott A. Gangloff sold 848 shares of Akero Therapeutics stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $54.84, for a total value of $46,504.32. Following the completion of the sale, the chief technology officer owned 23,452 shares of the company's stock, valued at $1,286,107.68. This trade represents a 3.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 241,229 shares of company stock worth $11,933,685 in the last three months. 7.07% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. RTW Investments LP increased its position in Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after purchasing an additional 940,388 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Akero Therapeutics by 11.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company's stock worth $194,997,000 after buying an additional 495,119 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Akero Therapeutics by 14.2% in the 1st quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company's stock worth $171,256,000 after buying an additional 526,233 shares during the period. Deep Track Capital LP raised its position in shares of Akero Therapeutics by 116.0% in the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after buying an additional 800,216 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Akero Therapeutics by 93.3% in the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after acquiring an additional 557,794 shares during the last quarter.

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $51.57 on Monday. The firm has a market capitalization of $4.11 billion, a PE ratio of -26.45 and a beta of -0.15. Akero Therapeutics has a 52 week low of $21.34 and a 52 week high of $58.40. The firm's 50-day simple moving average is $49.59 and its 200 day simple moving average is $43.70. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. On average, equities research analysts predict that Akero Therapeutics will post -3.99 EPS for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.